Fan, Y.-C.Y.-C.FanSheu, S.-Y.S.-Y.SheuLai, H.-T.H.-T.LaiChang, M.-H.M.-H.ChangChen, P.-H.P.-H.ChenLei, Y.-C.Y.-C.LeiTZONG-FU KUOWang, C.-Y.C.-Y.Wang2018-09-102018-09-102015http://www.scopus.com/inward/record.url?eid=2-s2.0-84940535357&partnerID=MN8TOARShttp://scholars.lib.ntu.edu.tw/handle/123456789/390490Danofloxacin is an antibacterial drug of the fluoroquinolone group developed for therapeutic purposes in veterinary medicine. The studies described here include investigations of the residues following a single dose or multiple doses of danofloxacin. Residue depletion studies were performed to determine residues in plasma and tissues of saltwater tilapia fish (Oreochromis mossambicus) after a single oral administration of danofloxacin at the dose of 10 mg/kg body weight and also after daily dose of 10 mg/kg body weight for five consecutive days. Danofloxacin residues were analyzed by HPLC with fluorescence detection. Following a single oral dose, danofloxacin residues in 6 h postdosing tilapia were at a maximum of 1.44, 12.48, and 13.18 μg/g in serum, liver, and kidney samples, respectively, while a peak muscle concentration of 2.15 μg/g was reached at 12 h. From single-dose data, the concentration of danofloxacin in serum, muscle, liver, and kidney samples declined with half-lives of 29, 34, 49, and 44 h, respectively. Based on the maximum residue level (MRL) of 0.1 μg/g in edible tissue for fin fish, the withdrawal times of danofloxacin in muscle were estimated to fall below the MRL after a withdrawal period of 21 days following the multiple-dose administration. These results may be helpful to regulatory agencies as they determine what tissues should be monitored to ensure that the established residue safety tolerance levels are not exceeded.[SDGs]SDG6[SDGs]SDG14journal article10.5740/jaoacint.13-327